Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 5, 2016, Pages

  Gallardo, Carmen R ^a   Rigau Comas, David ^b   Valderrama Rodríguez, Angélica ^c   Roqué i Figuls, Marta ^b   Parker, Lucy Anne ^d   Caylà, Joan ^b   Bonfill Cosp, Xavier ^e  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT; DRUG COMBINATION;

ARTHRALGIA; COCHRANE LIBRARY; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; DRUG TREATMENT FAILURE; EMBASE; FIXED DOSE COMBINATION; GASTROINTESTINAL DISEASE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LIVER INJURY; LUNG TUBERCULOSIS; MEDLINE; NEUROPATHY; PARESTHESIA; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; RHEUMATIC DISEASE; SENSITIVITY ANALYSIS; SINGLE DRUG FORMULATION; SKIN DISEASE; SPUTUM CULTURE; SPUTUM SMEAR; SYSTEMATIC REVIEW; VESTIBULAR DISORDER; ADOLESCENT; ADULT; COMBINATION DRUG THERAPY; DRUG COMBINATION; FEMALE; MALE; MEDICATION COMPLIANCE; META ANALYSIS; MIDDLE AGED; PROCEDURES; TUBERCULOSIS, PULMONARY;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUBERCULOSIS, PULMONARY;

EID: 84968919007     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009913.pub2     Document Type: Review

References (69)

1. Bartacek A, Schütt D, Panosch B, Borek M, Rimstar 4-FDC Study Group. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease 2009;13(6):760-6.
2. Agounitestane D, Chiheb M, Khaled S, Ait Khaled N, Boulahbal F, Chaulet P. A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment. Revue des Maladies Respiratoires 1990;7(3):209-13.
3. Bellabas M, Khaled S, Khaled NA, Boulahbal F, Chaulet P. Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis. Revue des Maladies Respiratoires 1989;6(1):59-64.
4. Chaulet P, Boulahbal F, Groupe de Travail sur la Chimiothérapie de la Tuberculose. Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Tuberculosis and Lung Disease 1995;76(5):407-12.
5. Geiter LJ, O'Brien RJ, Combs DL, Snider DE Jr. United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide. Tubercle 1987;68(2 Suppl):41-6.
6. Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G, et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. The Journal of the American Medical Association 2011;305(14):1415-23.
7. Nunn AJ, Cook SV, Burgos M, Rigouts L, Yorke-Edwards V, Anyo G, et al. Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis. International Journal of Tuberculosis and Lung Disease 2014;18(10):1252-4.
8. Munteanu I, Husar I, Didilescu C, Stoicescu IP. Considerations about the efficiency of treatment regimens with fixed Rifampicin-Isoniazid combinations in pulmonary tuberculosis. Pneumologia 2004;53(1):23-5.
9. Research Committee of the Tuberculosis Association of India. Fifth tuberculosis association of India: short course chemotherapy trial. Indian Journal of Tuberculosis 1989;36(2):95-101.
10. Semenova OV. Assessment of the use of a multicomponent drug in the treatment of new cases of pulmonary tuberculosis. Problemy Tuberkuleza i Boleznei Legkikh 2003;(11):22-5.
11. Su WJ, Perng RP. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. International Journal of Tuberculosis and Lung Disease 2002;6(11):1029-32.
12. Gravendeel JM, Asapa AS, Becx-Bleumink M, Vrakking HA. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis 2003;83(1-3):183-6.
13. Suryanto AA, Van den Broek J, Hatta M, de Soldenhoff R, van der Werf MJ. Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia?. International Journal of Tuberculosis and Lung Disease 2008;12(2):174-9.
14. Anonymous . Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. American Review and Respiratory Disease 1991;143(4 Pt 1):707-12.
15. Teo SK. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. International Journal of Tuberculosis and Lung Disease 1999;3(2):126-32.
16. Wu JT, Chiu CT, Wei YF, Lai YF. Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment. Clinics (São Paulo) 2015;70(6):429-34.
17. Zaka-Ur-Rehman Z, Jamshaid M, Chaudhry A. Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients. Pakistan Journal of Pharmaceutical Sciences 2008;21(2):185-94.
18. Zhang LX, Kan GQ, Tu DH, Wan LY, Faruqi AR. Fixed-dose combination chemotherapy versus multiple, single-drug chemotherapy for tuberculosis. Current Therapeutic Research 1996;57(11):849-56.
19. Zhu L, Yan B, Ma W. Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Disease] 1998;21(11):645-7.
20. Brändli O, Haegi V, Villiger B, Bohn W, Baumann HR, Zäch R. Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years. Schweizerische Medizinische Wochenschrift 1989;119(10):299-305.
21. Brändli O, Dreher D, Morger D. Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide. Schweizerische Medizinische Wochenschrift 1993;123(25):1300-6.
22. Chu N, Gao M, Ma L. Controlled clinical study on efficacy of national fixed-dose compounds in antituberculosis chemotherapy. Respirology. Proceedings of the 9th Congress of the Asian Pacific Society of Respirology; 2004 Dec 10-13; Hong Kong. Hong Kong, 2004; Vol. 9 Suppl:72.
23. Cowie RL, Brink BA. Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazid-pyrazinamide combination tablet. South African Medical Journal 1990;77(8):390-1.
24. Dubra F. Controlled therapeutic trial with the combination rifampicin-isoniazid given for six months to previously untreated patients with pulmonary tuberculosis. Bulletin of the International Union against Tuberculosis and Lung Disease 1972;47:37-40.
25. Ferreira AC, Silva Júnior JL, Conde MB, Rabahi MF. Clinical treatment outcomes of tuberculosis treated with the basic regimen recommended by the Brazilian National Ministry of Health using fixed-dose combination tablets in the greater metropolitan area of Goiânia, Brazil. Jornal Brasileiro de Pneumologia [Brazilian Journal of Pulmonology] 2013;39(1):76-83.
26. Glatthaar E, Summers FS, Carleir ND. A comparative community-based therapy trial with single combination product (Rifater-80). CHASA; Journal of Comprehensive Health 1991;2:155-8.
27. González Montaner LJ, Palma Beltran O, Abbate E, Gini G. A comparison of the therapeutic efficacy of two drug combinations in cases of previously untreated open tuberculosis. Praxis und Klinik der Pneumologie 1978;32(11):717-20.
28. Herman N, Aditama TY, Ikhsan M. Comparison of antituberculosis drugs between fixed dose combination and combipack for new cases of pulmonary tuberculosis in community health centres. Respirology. Proceedings of the 12th Congress of the Asian Pacific Society of Respirology. 2007; Vol. 12 (Suppl. 4):A238.
29. Anonymous . Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council. The American Review of Respiratory Disease 1991;143(4 Pt 1):700-6.
30. Hong Kong Chest Service/British Medical Research Council. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy. The American Review of Respiratory Disease 1989;140(6):1618-22.
31. ISRCTN95204603 . Comparison of four Fixed Dose Combinations versus standard treatment with separate anti-TB drugs for treatment of pulmonary tuberculosis. http://www.controlled-trials.com/ISRCTN95204603 (accessed 14 July 2014). [ISRCTN95204603]
32. Macnab MF, Bohmer PD, Seager JR. Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. South African Medical Journal 1994;84(6):325-8.
33. Merle CS, Sismanidis C, Sow OB, Gninafon M, Horton J, Lapujade O, et al. A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project. Trials 2012;13:61.
34. Punnotok J, Pumprueg U, Chakorn T. A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up. Journal of the Medical Association of Thailand 1995;78(6):298-304.
35. Soehardiman D, Soepandi P, Nawas A. Comparison of Antituberculosis Drugs Between Fixed Dose Combinationand Combipack for New Cases of Pulmonary Tuberculosis in Persahabatan Hospital. Respirology. Proceedings of the 12th Congress of the Asian Pacific Society of Respirology. 2007; Vol. 12 (Suppl 4):A237.
36. Sokolova GB, Koriakin VA, Khalbaeva IV, Elistratova NA, Ziia AV. Combined chemotherapy of patients with tuberculosis - new regimens and dosage forms. Problemy tuberkuleza 1993;(5):21-3.
37. Xu WG, Lu W, He HJ, Gu XR. Randomized control study on domestic fixed-dose combinations in the initial treatment of smears positive tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Jjournal of Tuberculosis and Respiratory Diseases] 2004;27(10):690-3.
38. Liang Y, Yan XX, Wang JY, et al. Curative effect of fixed-dose anti-tuberculosis combinations in primary treatment of tuberculosis. Chinese Journal of Anti-tuberculosis Association 2007;29(2):180-1.
39. Ma LP, Wu XG, Chu NH, Zhu L, Shan B, Wang M, et al. Feasibility study of domestic four-drug fixed-dose combination under DOTS as initial treatment in patients with smear positive pulmonary tuberculosis. Chinese Journal of Anti-tuberculosis Association 2010;61(5):21-5.
40. Zhao QR, Tian M, Pan R, Huang B, Gan L, Shan B, et al. Randomized control study on domestic 4FDC/2FDC combinations in initial treatment of smear positive tuberculosis patients. Parastosis and Infectious Disease 2007;15(3):122-7.
41. Zhu LZ, Yan BY. Controlled clinical study on efficacy of fixed-dose compounds rifinah in anti-tuberculosis chemotherapy: results of two-year follow-up. Tuberculosis and Thoracic Tumor 2000;48(5):320.
42. Agounitestane D, Chiheb M, Khaled S, Ait Khaled N, Boulahbal F, Chaulet P. A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment. Revue des Maladies Respiratoires 1990;7(3):209-13.
43. Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations. International Journal of Clinical Pharmacology and Therapeutics 2002;40(10):474-81.
44. Albanna AS, Smith BM, Cowan D, Menzies D. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. The European Respiratory Journal 2013;42(3):721-32.
45. Bellabas M, Khaled S, Khaled NA, Boulahbal F, Chaulet P. Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis. Revue des Maladies Respiratoires 1989;6(1):59-64.
46. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bulletin of the World Health Organization 2001;79(1):61-8.
47. Centers for Disease Control and Prevention. Treatment of Tuberculosis. Vol. MMWR 52[RR-11], American Thoracic Society, CDC, and Infectous Diseases Society of America, 2003.
48. Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bulletin of the World Health Organization 2004;82(12):935-9.
49. Gravendeel JM, Asapa AS, Becx-Bleumink M, Vrakking HA. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis 2003;83(1-3):183-6.
50. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
51. TB CARE I. International Standards for Tuberculosis Care (ISTC). 3. The Hague: TB CARE I, 2014.
52. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
53. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. Clinical Guidelines, CG33. London: National Collaborating Centre for Chronic Conditions, 2006.
54. National Collaborating Centre for Chronic Conditions and Centre for Clinical Practice at National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: NICE, 2011.
55. Nunn AJ, Cook SV, Burgos M, Rigouts L, Yorke-Edwards V, Anyo G, et al. Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis. The International Journal of Tuberculosis and Lung Disease 2014;18(10):1252-4.
56. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
57. Rieder HL. Interventions for Tuberculosis Control and Elimination. Paris: International Union Against Tuberculosis and Lung Disease, 2002.
58. Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. American Review of Respiratory Disease 1991;143(4 Pt 1):707-12.
59. Wells WA, Konduri N, Chen C, Lee D, Ignatius HR, Gardiner E, et al. Implications of the current tuberculosis treatment landscape for future regimen change. The International Journal of Tuberculosis and Lung Disease 2011;15(6):746-53.
60. World Health Organization. Operational guide for National Tuberculosis Control Programmes on the introduction and use of fixed-dose combination drugs. WHO/CDS/TB/2002.308. http://apps.who.int/medicinedocs/en/d/Js4872e/ (accessed 13 March 2016).
61. World Health Organization. Dosing instructions for the use of currently available fixed-dose combination TB medicines for children. September 2009. http://www.who.int/tb/challenges/interim_paediatric_fdc_dosing_instructions_sept09.pdf (accessed 13 March 2016).
62. World Health Organization. Guidelines for treatment of tuberculosis. WHO/HTM/TB/2009.420. 4th Edition. Geneva: World Health Organization, 2010.
63. World Health Organization. WHO Model List of Essential Medicines. 17th Edition. Geneva: World Health Organization, 2011.
64. World Health Organization. Definitions and reporting framework for tuberculosis - 2013 revision (updated December 2014). http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf (accessed 9 March 2016).
65. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd Edition. Geneva: World Health Organization, 2014.
66. World Health Organization. Global Tuberculosis Report 2015. Geneva: World Health Organization, 2015.
67. Zhang HQ, Xi XE, Wang YL, Han W, Zhang CX, Jiao JH. Side effects of tuberculosis treatment with fixed-dose combinations. Journal of Biological Regulators and Homeostatic Agents 2015;29(2):379-88.
68. Zwolska Z, Niemirowska-Mikulska H, Augustynowicz-Kopec E, Walkiewicz R, Stambrowska H, Safianowska A, et al. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules. The International Journal of Tuberculosis and Lung Disease 1998;2(10):824-30.
69. Gallardo CR, Rigau Comas D, Valderrama Rodríguez A, Roqué i Figuls M, Parker LA, Caylà J, et al. Fixed-dose combinations of drugs versus single drug formulations for treating pulmonary tuberculosis. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD009913]